

Special Issue

Molecular Research on Growth Hormones and Related Hormones and Peptides

Message from the Guest Editor

Over a century after the discovery of human growth hormone (HGH), its approved clinical applications remain limited. Nevertheless, increasing evidence suggests that HGH and its mediator insulin-like growth factor 1 (IGF-1) may enhance healthspan and quality of life in older adults. Prolactin, a related protein, is under active investigation for therapeutic uses. Vasoinhibin, a prolactin-derived fragment with antiangiogenic properties, shows promise in treating angiogenesis-dependent diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis. In veterinary medicine and animal biotechnology, growth hormones have potential applications ranging from treating pituitary disorders in companion animals to improving livestock production traits. However, their broader use has been constrained by the high cost and low competitiveness of recombinant manufacturing methods.

Guest Editor

Dr. Hugo Alberto Barrera-Saldaña

Facultades de Medicina y Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, Mexico

Deadline for manuscript submissions

31 March 2026



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/257044

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and
other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 17.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names are published annually in the journal.